Cambridge, MA-based Bluebird Bio (NASDAQ: BLUE) has named Susanna High, formerly of Alnylam Pharmaceuticals and Millennium Pharmaceuticals, its chief operating officer. Andrew Obenshain, a veteran of Shire and Genzyme before that, will lead Bluebird’s operations in Europe.
Xconomy Insight · Special Report
Industry experts explain what it takes to launch a new biotech company
Sponsored · Whitepaper
How a patient-centric, technology-driven approach can broaden access to research and reach patients regardless of geography, ethnicity, sex, or gender
PRA Health Sciences
Sponsored · Special Report
Hyperinflation in rents is over
Hughes Marino
